2 Information about lanadelumab

Information about lanadelumab

Marketing authorisation indication

Lanadelumab (Takhzyro, Shire) is indicated for 'routine prevention of recurrent attacks of hereditary angioedema in patients aged 12 years and older'.

Dosage in the marketing authorisation

The recommended starting dose is 300 mg lanadelumab every 2 weeks. The summary of product of characteristics states that in patients who are stably attack-free on treatment, a dose reduction of 300 mg lanadelumab every 4 weeks may be considered, especially in patients with low weight. It is administered as a subcutaneous injection.


The list price for lanadelumab is £12,420 per 300-mg vial.

The company has a commercial arrangement. This makes lanadelumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)